Assessing breast cancer risk in women

American Family Physician

Volumn 78, Issue 12, 2008, Pages 1361-1366

  Steiner, Elizabeth ^a   Klubert, David ^a   Knutson, Doug ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIETHYLSTILBESTROL; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; BREAST CANCER; BREAST DISEASE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; DIET THERAPY; DISEASE ASSOCIATION; EARLY MENOPAUSE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC PREDISPOSITION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; MAMMOGRAPHY; MEDICAL ASSESSMENT; MENARCHE; OBESITY; PARITY; PATIENT COUNSELING; PHYSICIAN; PREGNANCY; PRIMIGRAVIDA; REVIEW; RISK FACTOR; SEX DIFFERENCE; TUMOR BIOPSY; ARTICLE; BREAST TUMOR; FEMALE;

BREAST NEOPLASMS; FEMALE; HUMANS; RISK FACTORS;

EID: 58849146255     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. American Cancer Society. Cancer Facts and Figures, 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed November 19, 2008.
2. Nelson HD, Huffman LH, Fu R, Harris EL, for the USPSTF. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force [published correction appears in Ann Intern Med. 2005;143(7):547]. Ann Intern Med. 2005;143(5):362-379.
3. Claus EB. Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam Cancer. 2001;1(3-4):197-206. (Pubitemid 35407944)
4. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-366. (Pubitemid 32229380)
5. Olson JE, Sellers TA, Iturria SJ, Hartmann LC. Bilateral oopherectomy and breast cancer risk reduction among women with a family history. Cancer Detect Prev. 2004;28(5):357-360. (Pubitemid 39471282)
6. Eisen A, Lubinski J, Klijn J., et al. Breast cancer following bilateral oopherectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491-7496. (Pubitemid 46291812)
7. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med. 1994;330(2):81-87.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet. 2002;360(9328):187-195.
9. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 1994;331(1):5-9. (Pubitemid 24195593)
10. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47. (Pubitemid 23269069)
11. McTiernan A, Kooperberg C, White E, et al, for the Women's Health Initiative Cohort Study. Recreational physical activity and the risk of breast cancer in postmenopausal women. JAMA. 2003;290(10):1331-1336. (Pubitemid 37442629)
12. McTiernan A. Physical activity and the prevention of breast cancer. Medscape Womens Health. 2000;5(5):E1.
13. Biglia N, Defabiani E, Ponzone R, Mariani L, Marenco D, Sismondi P. Management of risk of breast carcinoma in postmenopausal women. Endocr Relat Cancer. 2004;11(1):69-83. (Pubitemid 38419724)
14. Eng-Wong J, Zujewski JA. Raloxifene and its role in breast cancer prevention. Expert Rev Anticancer Ther. 2004;4(4):523-532. (Pubitemid 39161986)
15. Vogel VG, Costantino JP, Wickerham DL, et al., for the National Surgical Adjuvant Breast and Bowel Project. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [published corrections appear in JAMA. 2006;296(24):2926 and JAMA. 2007;298(9):973]. JAMA. 2006;295(23):2727-2741.
16. Hamajima N, Hirose K, Tajima K, et al., for the Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234-1245.
17. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229-237. (Pubitemid 41058322)
18. Laden F, Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health. 1998;19:101-123. (Pubitemid 28279926)
19. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(1):3-15. (Pubitemid 38420778)
20. Hartman AR. The problems with risk selection; scientific and psychosocial aspects. Recent Results Cancer Res. 2005;166:125-144.
21. Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med. 2005;9(1):208-221.
22. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389-1399.
23. Arai M, Utsunomiya J, Miki Y. Familial breast and ovarian cancers. Int J Clin Oncol. 2004;9(4):270-282. (Pubitemid 39277922)
24. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer [published correction appears in Lancet. 1997;350(9089):1484]. Lancet. 1997;350(9084):1047-1059.
25. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
26. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81(10):1290-1302. (Pubitemid 44484967)
27. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-2032. (Pubitemid 34680593)
28. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236. (Pubitemid 46143226)
29. Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol. 2002;12(1):21-26. (Pubitemid 34003068)
30. Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr. 2004;79(2):282-288. (Pubitemid 41095982)
31. Steiner E, Klubert D, Hayes M, Hamilton A, Kolasa K. Clinical inquiries. Does a low-fat diet help prevent breast cancer? J Fam Pract. 2007;56(7):583-584.
32. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295(6):629-642. (Pubitemid 43209065)
33. Smith-Warner SA, Spiegelman D, Yuan SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA. 2001;285(6):769-776. (Pubitemid 32167236)
34. van Gils CH, Peeters PH, Bueno-de-Mesquita HB, et al. Consumption of vegetables and fruits and risk of breast cancer. JAMA. 2005;293(2):183-193. (Pubitemid 40095869)
35. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk: review of the epidemiological evidence. IARC Sci Publ. 2002;156:331-336.
36. Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiology. 2005;16(5):688-690.
37. García Rodríguez LA, González-Pérez A. Use of antibiotics and risk of breast cancer. Am J Epidemiol. 2005;161(7):616-619. (Pubitemid 40411089)
38. Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat. 2005;92(2):163-167. (Pubitemid 40933581)
39. Sørensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer. 2005;92(3):594-596. (Pubitemid 40395544)
40. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA. 2004;291(7):827-835. (Pubitemid 38543770)
41. Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(1):261-264. (Pubitemid 40165311)
42. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805-812. (Pubitemid 40909123)
43. Harris RE, Chlebowski RT, Jackson RD, et al., for the Women's Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63(18):6096-6101. (Pubitemid 37187516)
44. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology. 2005;68(1):40-47. (Pubitemid 40675007)
45. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291(20):2433-2440. (Pubitemid 38669186)
46. Beral V, Bull D, Doll R, Peto R, Reeves G, for the Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007-1016.
47. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5 pt 1):347-360. (Pubitemid 34977137)
48. Knutson D, Steiner E. Screening for breast cancer: current recommendations and future directions. Am Fam Physician. 2007;75(11):1660-1666. (Pubitemid 46954082)
49. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, Pa.: Lippincott, Williams & Wilkins; 2005.
50. Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethystilbesterol in pregnancy. Further follow-up. JAMA. 1993;269(16):2096-2100. (Pubitemid 23112627)
51. Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbesterol in utero. JAMA. 1998;280(7):630-634. (Pubitemid 28502640)
52. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol. 2004;16(1):19-25. (Pubitemid 38241538)
53. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1401-1411. (Pubitemid 27475968)
54. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst. 2006;98(2):110-115. (Pubitemid 43159965)
55. U.S. Preventive Services Task Force. Preventive medication: breast cancer. http://www.ahrq.gov/clinic/uspstf/uspsbrpv.htm#summary. Accessed November 17, 2007.
56. Nagata C, Mizoue T, Tanaka K, et al., for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006;36(6):387-394.
57. Johnson KC. Accumulating evidence on passive and active smoking and breast cancer risk. Int J Cancer. 2005;117(4):619-628. (Pubitemid 41504550)